The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Prostate cancer screening is essential for early detection, especially in high-risk groups like men over 50, African Americans, and those with a family history. Routine screening, including PSA tests ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Data from Vista Health, a leading UK provider of private diagnostic services, has revealed the worrying knowledge gap when it comes to the prostate, as 26 percent of men do not know what their ...